Phase II Study to Evaluate the Efficacy and Safety of Nivolumab as Postoperative Adjuvant Therapy in Patients with Esophageal Cancer Treated with Preoperative DCF Treatment - PENTAGO

Goto Hironobu0 个研究点目标入组 130 人开始时间: 2023年1月22日最近更新: 2023年11月20日

试验速览

暂无简介。

•Patients who meet all of the following criteria are eligible
•1.Primary tumor is located in the thoracic esophagus and is histologically diagnosed as squamous cell carcinoma by endoscopic biopsy.
•2.Patient underwent radical resection after preoperative DCF therapy without pathologic complete response.
•3.Patients must be at least 18 years of age on the date of enrollment.
•4.Gender is irrelevant.
•5.PS is 0 or 1 by ECOG criteria.
•6.Patients can be enrolled between 4-16 weeks (28-112 days postoperatively) after complete resection.
•7.Patients must be confirmed disease-free by thoracoabdominal CT within 4 weeks prior to enrollment.
•8.The latest laboratory values within 14 days prior to enrollment (the same day of the week 2 weeks prior to enrollment is acceptable) meet all of the following
•9.The patient has given his/her free and voluntary written consent to participate in this clinical research.

•Patients with any one of the following will be excluded
•1) Have an active systemic infection.
•2) Have an active autoimmune disease.
•3) Requires treatment with systemic corticosteroids (prednisone equivalent >10 mg/day; inhaled and topical steroids and hormone replacement therapy are acceptable) or other immunosuppressive agents (use for adverse events is acceptable).
•4) Currently or previously receiving treatment with immune checkpoint inhibitors.
•5) History of interstitial lung disease or extensive findings of these on CT.
•6) Other patients deemed inappropriate by the investigators of this clinical study.
•7) Unwilling contraceptive patients and pregnant and lactating women.

发起方

Goto Hironobu